Combination of doxorubicin-based chemotherapy and polyethylenimine/p53 gene therapy for the treatment of lung cancer using porous PLGA microparticles

- Porous PLGA microparticles harboring doxorubicin and PEI25K/p53 were prepared and characterized.
- The microparticles exhibited an enhanced anticancer effect due to the synergistic cytotoxicity of doxorubicin and p53.
- The microparticles provided a potential local drug delivery system by inhalation.